Feb. 16, 2016
On Feb. 16, 2016 Korea-based Genexine Inc. announced that it has entered into a license agreement with Shanghai ChemoWanbang Biopharma Co., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., for the development and commercialization of GX-E2 (EPO-hyFc), a novel Fc-engineered (hyFc) long acting EPO for anemia due to chronic kidney disease and chemotherapy.
GX-E2, currently in phase II clinical trial in Korea, was created by Genexine and co-developed by Genexine and Green Cross.
Under the terms of the agreement, ChemoWanbang will have the right to develop and commercialize GX-E2 in the territory of China, excluding Hong Kong, Macau and Taiwan. Genexine will receive clinical and commercial milestones up to USD$44.5 million plus sales-based royalties.